Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Goebell, Peter J
ARASAFE, NCT05676203: A Trial Comparing Docetaxel 75 mg/m2 (3w) Versus Docetaxel 50 mg/m2 (2w) in Combination With Darolutamide + ADT in mHSPC Patients	Recruiting	3	250	Europe	Standard ADT (androgen deprivation therapy), Standard Darolutamide, Docetaxel	Jena University Hospital, Bayer	Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)	07/25	01/27
FOKAL-BT, NCT02391051: Focal Brachytherapy in Patients With Selected "Low-risk" Prostate Cancer - a Phase-II-trial	Recruiting	2	50	Europe	HDR-Brachytherapy	University of Erlangen-Nürnberg Medical School	Prostate Cancer	12/19	12/29
CARAT, NCT03374267: Registry Platform Urologic Cancer	Recruiting	N/A	1830	Europe	Routine care as per site standard.	iOMEDICO AG	Renal Cell Carcinoma, Urothelial Carcinoma	06/27	06/27